AssigneesThe United States of America as represented by the United States National Aeronautics and Space Administration, University of Houston, Universities Space Research Association
InventorsMark S. F. Clarke, Alamelu Sundaresan, Neal R. Pellis
The present disclosure provides ex vivo-derived mineralized three-dimensional bone constructs. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions. Preferably, the randomized gravity vector conditions are obtained using a low shear stress rotating bioreactor, such as a High Aspect Ratio Vessel (HARV) culture system. The bone constructs of the disclosure have utility in physiological studies of bone formation and bone function, in drug discovery, and in orthopedics.
Drawings
Claims14
A method for promoting formation of a three-dimensional osteogenic cell aggregate ex vivo, the method comprising:
(a) introducing osteoclast precursors and osteoblasts into a cylindrical culture vessel that rotates about a central horizontal axis,
wherein said cylindrical culture vessel contains a matrix-free culture medium, wherein the matrix-free culture medium does not comprise an exogenous scaffolding material that guides formation of the three-dimensional osteogenic cell aggregate,
(b) co-culturing said osteoblasts and said osteoclast precursors in said cylindrical culture vessel during horizontal rotation at a rate of between 1 and 2 rotations per minute to promote scaffold-free interaction, aggregation and organization of said osteoclast precursors and said osteoblasts until the three dimensional tissue constructs are formed,
(c) further culturing, the tome dimensional aggregate of step (b) in a matrix-free mineralization culture medium in said cylindrical culture vessel at a higher average rate of horizontal rotation than the average rate of horizontal rotation during step (b) to increase perfusion and thereby to form mature three dimensional mineralized osteogenic cell aggregate composed of osteoblasts and osteoclasts differentiated from osteoclast precursors,
wherein mineralized three dimensional osteogenic cell aggregate comprise an outer zone comprising osteoclasts surrounding an inner porous core comprising osteoblasts and/or osteocytes encased in a mineralized extracellular matrix.
11/693,662Filed 29 Mar 2007 · us provisional application
Priority
30 Mar 2006
Published
US 2009/0061479 A15 Mar 2009
Granted
13 Dec 2011
Term ends
27 Feb 2029Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment, including 701 days of adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
Containing added animal cells: using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
Life of this patent
About 2 years 4 months of term left · ends 27 Feb 2029 (estimated)
Priority30 Mar 2006
Filed29 Mar 2007
Published5 Mar 2009
Granted13 Dec 2011
Today12 Oct 2026
Term ends27 Feb 2029
Priority30 Mar 2006
Granted13 Dec 2011
Term ends27 Feb 2029
Priority claimedParent application 60/787,431
Application filedUS 11/693,662
PublishedUS 2009/0061479 A1
Assigned to National Aeronautics and Space Administrationassignment of assignor's interest
Assigned to University of Houstonassignment of assignor's interest
Assigned to Universities Space Research Associationassignment of assignor's interest
GrantedUS 8,076,136 B2
TodayWithin its term
Term endsEstimated, includes 701 days of adjustment
Description6,828 words
Summary1,058 words
#The invention relates to ex vivo-derived mineralized three-dimensional bone constructs which replicate natural bone.
#One of the central problems associated with studying both the normal and pathophysiology of bone is that as an organ system it is slow growing and the time to show an observable response to a particular stimulus is relatively long. The nature of the mineralized tissue matrix of bone in vivo and its complex architecture also presents several technical problems associated with how experimental observations can be made. At present, truly informative studies designed to understand bone physiology have relied primarily on the removal of samples of bone tissue from normal or diseased tissue either in a clinical setting or from experimental animal models.
#To date, there is no three dimensional tissue culture model of bone, either of animal or human origin. The prior art has relied primarily on the use of monotype cell type cultures of osteoblasts or osteoclast cells grown on planar, two dimensional tissue culture surfaces. Such cultures have also been grown in three dimensional collagen support gels and some investigators have utilized culture systems that allow types of mechanical strain to be applied to the cells in order to study the effects of mechanical loading. However, these cultures have been primarily focused on the responses of a single cell type, such as osteoblasts, to various environmental stimuli.
Brief description of the drawings7 figures
#FIG. 1 is a flowchart of an example of a method for preparing mineralized three-dimensional bone constructs.
#FIGS. 2A-2B present images of mineralized three-dimensional bone constructs at 14 days of mineralization (FIG. 2A) and 21 days of mineralization (FIG. 2B). The scale bars each represent 1 cm.
#FIGS. 3A-3B present images of mineralized three-dimensional bone constructs. FIG. 3A presents a fluorescence confocal microscopy image of an optical section through bone constructs in which the osteoclast precursor cells were labeled with a fluorescent cell tracking dye (observable as white spots in FIG. 3A). FIG. 3B shows the same constructs viewed in incident laser light (i.e. non-fluorescent illumination) to illustrate the shape of the constructs. The scale bar in each of FIG. 3A and FIG. 3B is 200 μm.
Detailed description5,329 words
#In one aspect, the present disclosure provides mineralized three-dimensional bone constructs (sometimes referred to herein simply as “bone constructs”). The mineralized three dimensional constructs of the disclosure are “bone like” in appearance by visual inspection, in certain important respects resembling trabecular bone (also known in the art as “spongy bone”). In preferred embodiments, the mineralized three-dimensional bone constructs of the disclosure are macroscopic in size and are approximately spheroidal in shape, preferably between about 200 μm and about 4 mm in diameter; however, larger and smaller bone constructs are specifically contemplated.
#The bone constructs comprise an inner core surrounded by an outer layer. The inner core comprises a three-dimensional crystalline matrix that stains positively with Alizarin Red S stain and with the von Kossa histochemical stain, indicating that it comprises mineral elements observed in normal human bone in vivo, including calcium, phosphates, and carbonates. The inner core also comprises osteoblasts and/or osteocytes embedded within the crystalline matrix, and is preferably devoid of necrotic tissue. Osteocytes are developmentally inactive cells found only in native bone tissue in vivo and are believed to be formed from osteoblasts that have become trapped in the crystalline matrix. The outer layer is comprised of osteoclasts, which may express the differentiation marker osteocalcein. The cell types in the bone constructs of the disclosure can be obtained from any mammalian species, but are preferably obtained from humans.
#In another aspect, the disclosure provides methods for producing the mineralized three-dimensional bone constructs. In general, the bone constructs of the disclosure are produced by culturing osteoclast precursors and osteoblasts together under randomized gravity vector conditions (approaching those conditions that cultured cells experience during microgravity culture) in a matrix-free culture medium. Osteoclast precursors may be obtained from bone marrow and/or peripheral blood lymphocytes by techniques well known in the art. Osteoclast precursors may also be obtained from commercial sources (for example, from Cambrex/Lonza, Inc.). Osteoblasts, preferably primary human osteoblasts, may also be obtained by techniques well known in the art, and may also be obtained from commercial sources (for example, from PromoCell, Inc. and from Cambrex/Lonza, Inc.). A “matrix-free culture medium” is a cell culture medium which does not include carrier material (such as microcarrier beads or collagen gels) onto which osteoblasts and osteoclast precursors can attach. Suitable cell culture media include Eagle's Minimal Essential Medium (EMEM) or Dulbecco's Modified Eagle's Medium (DMEM), preferably supplemented with fetal bovine serum (FBS). Preferably, the matrix-free culture medium also comprises osteoblast growth supplements such as ascorbic acid. The matrix-free culture medium preferably also further comprises osteoclast differentiation factors, such as Receptor Activator of NF-kB (RANK) ligand and macrophage colony stimulating factor (M-CSF). For example, in one embodiment the matrix-free culture medium comprises FBS-supplemented DMEM, ascorbic acid, RANK ligand, and M-CSF. Example 2 includes a description of one suitable matrix-free culture medium.